Crawford Investment Counsel Boosts Stake in CONMED Corporation

The investment firm increased its holdings in the medical technology company by 12.6% in the third quarter.

Mar. 15, 2026 at 11:11am

Got story updates? Submit your updates here. ›

Crawford Investment Counsel Inc. increased its stake in CONMED Corporation (NYSE:CNMD) by 12.6% during the third quarter, according to a recent SEC filing. The firm now owns 323,998 shares of the company's stock, valued at approximately $15.2 million. CONMED is a global medical technology company headquartered in Utica, New York that develops, manufactures, and markets surgical devices and accessories for minimally invasive procedures.

Why it matters

This filing provides insight into the investment strategy and portfolio decisions of Crawford Investment Counsel, a prominent investment management firm. The increased stake in CONMED suggests the firm sees growth potential in the medical technology company, which operates in the orthopedics, general surgery, gastroenterology, and gynecology markets.

The details

According to the 13F filing, Crawford Investment Counsel purchased an additional 36,186 shares of CONMED during the third quarter, bringing its total position to 323,998 shares. This represents approximately 1.05% of CONMED's outstanding shares. The investment firm cited CONMED's diverse product portfolio and market position as factors behind the increased stake.

  • The 13F filing covers the third quarter of 2026.

The players

Crawford Investment Counsel Inc.

An investment management firm that increased its stake in CONMED Corporation during the third quarter of 2026.

CONMED Corporation

A global medical technology company headquartered in Utica, New York that develops, manufactures, and markets surgical devices and accessories for minimally invasive procedures.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the investment strategy of Crawford Investment Counsel, which sees growth potential in CONMED's medical technology business. The increased stake suggests the firm believes CONMED is well-positioned to capitalize on trends in the orthopedics, general surgery, gastroenterology, and gynecology markets.